Patent · US Active

Process for the preparation of (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid

US9975856B2 · kind B2 · utility

0Cited by

4References

13Claims

0Family size

Assignee

Genentech, Inc. · US

Inventors

Stephan Bachmann · Allschwil, CH
Serena Maria Fantasia · Saint-Louis, FR
Francis Gosselin · South San Francisco, US
Chong Han · Foster City, US
Stefan Hildbrand · Riehen, CH
Theresa Humphries · San Francisco, US
Christian JENNY · Basel, CH
Ngiap-Kie Lim · South San Francisco, US
Andrew McClory · South San Francisco, US
Christian Moessner · Lörrach, DE
Pankaj D. Rege · Basel, CH
Scott Savage · Redwood City, US
Haiming Zhang · Pennington, US

Key dates

Filing date	Oct 6, 2016
Grant date	May 22, 2018
Priority date	—
Expiry date	Oct 6, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07F5/04
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Processes are described for the preparation of estrogen receptor modulating compound, (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid I:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.